D-0215-2026 Class II Ongoing
FDA drug recall D-0215-2026 was initiated by Breckenridge Pharmaceutical, Inc. on Nov 24, 2025 and is designated Class II. Reason for recall: CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit The recall status is ongoing. Affected quantity: 3397 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Dec 10, 2025
- Initiation Date
- Nov 24, 2025
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 3397 bottles
Product description
Duloxetine Delayed-Release Capsules, USP, 60 mg, 1000-Capsule bottles, Rx Only, Manufactured by: Towa Pharmaceuticals Europe, S.L. Marotrelles, (Barcelona), Spain, Manufactured for : Quallient Pharmaceuticals Health, LLC, Grand Cayman, Cayman Islands, NDC 82009-032-10.
Reason for recall
CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
Distribution pattern
Nationwide within the United States
Code information
Lot #: 240947C, 240962C, Exp. Date 04/2027
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0215-2026
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026